Article
Pharmacology & Pharmacy
Suping Niu, Min Chen, Diqin Yan, Xiangxing Liu, Shuren Guo, Lun Ou, Huaying Fan, Jie Lv, Qian Wang, Wenliang Dong, Lin Xia, Simin Wang, Gang Liu, Qun Gu, Danjie Guo, Hongxia Liu, Huiying Rao, Qingshan Zheng, Xiaoyan Nie, Haifeng Song, Yi Fang
Summary: This study aimed to explore the safety and efficacy of LY06006 when administered subcutaneously in healthy Chinese adults. The results showed that single-dose subcutaneous administration of LY06006 was safe and well-tolerated in this population, and exhibited linear pharmacokinetic characteristics.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Kritika Gupta, Deepak Modi, Ratnesh Jain, Prajakta Dandekar
Summary: Monoclonal antibodies (mAbs) are important molecules in protein therapeutics, used in various fields such as immunology, oncology, and organ transplant. They have revolutionized targeted therapy and have immense potential for personalized treatment. Studies on mAb expressing clones against TNF-alpha aim to provide economic alternatives for research purposes and supplement limited industrial production.
MOLECULAR BIOTECHNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Hanjing Chen, Weili Chen, Fei Yuan, Qingcheng Guo, Xunmin Zhang, Chenguang Wang, Xuening Li
Summary: This study evaluated the bioequivalence of CMAB807, a biosimilar to denosumab, for the treatment of osteoporosis. The results showed that CMAB807 had similar pharmacokinetics, pharmacodynamics, safety, and immunogenicity to denosumab. CMAB807 could potentially be a new treatment option for patients with osteoporosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Infectious Diseases
Brianna M. Eales, Cole S. Hudson, Iordanis Kesisoglou, Weiqun Wang, Michael Nikolaou, Vincent H. Tam
Summary: Antimicrobial resistance is on the rise, leading to the common use of combination therapy for infections caused by multidrug resistant bacteria. A theoretical framework has been developed to simulate the pharmacokinetic profiles of three drugs with different half-lives, and experimental validation of this model has shown promising results. The validated benchtop setup provides a flexible preclinical tool to explore the effectiveness of various drug combinations against multidrug resistant bacteria.
Article
Pharmacology & Pharmacy
Siyi Wang, Xiaoyan Yang, Jie Huang, Shuang Yang, Qian Wu, Honghui Chen, Shuting Wu, Changlin Dou, Guoping Yang, Yuxia Xiang
Summary: This study compared the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of LY06006 (denosumab biosimilar) and denosumab in healthy Chinese adult male subjects. The results demonstrated that LY06006 and denosumab have similar characteristics and bioequivalence in pharmacokinetics, as well as similar pharmacodynamic profiles, safety, and immunogenicity.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2022)
Review
Medicine, Research & Experimental
Sean Chia, Shi Jie Tay, Zhiwei Song, Yuansheng Yang, Ian Walsh, Kuin Tian Pang
Summary: The circulatory half-life of recombinant therapeutic proteins is important for determining dosing frequency and treatment cost. Manipulating the N-glycan composition, particularly sialic acid, can extend the half-life by masking the terminal galactose recognized by the hepatic asialoglycoprotein receptor. This review provides an illustrative overview of strategies to enhance pharmacokinetic/ pharmacodynamic properties through manipulation of sialic acid content in recombinant therapeutic proteins.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Immunology
Andrew D. McCallum, Henry E. Pertinez, Laura J. Else, Sujan Dilly-Penchala, Aaron P. Chirambo, Irene Sheha, Madalitso Chasweka, Alex Chitani, Rose D. Malamba, Jamilah Z. Meghji, Stephen B. Gordon, Geraint R. Davies, Saye H. Khoo, Derek J. Sloan, Henry C. Mwandumba
Summary: This study aimed to describe the plasma and intrapulmonary pharmacokinetics of first-line anti-tuberculosis drugs and explore their relationships with clinical outcomes in patients with pulmonary tuberculosis. The research found differential drug concentrations between plasma and the lung, with accumulation of drugs at the site of disease potentially explaining the success of the first-line regimen. Low rifampicin concentrations observed in all compartments support ongoing clinical trials of high-dose rifampicin regimens.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Pharmacology & Pharmacy
Alexander Vugler, James O'Connell, Mai Anh Nguyen, Dietmar Weitz, Thomas Leeuw, Elizabeth Hickford, Alexander Verbitsky, Xiaoyou Ying, Markus Rehberg, Bruce Carrington, Mark Merriman, Andrew Moss, Jean-Marie Nicholas, Phil Stanley, Sara Wright, Tim Bourne, Yann Foricher, Daniel Brookings, Helen Horsley, Matthias Herrmann, Srinivas Rao, Markus Kohlmann, Peter Florian
Summary: This article reports the discovery and development of a potent small molecule inhibitor of TNF, SAR441566, which has shown potential as a treatment option for chronic autoimmune diseases. By stabilizing an asymmetrical form of TNF and compromising its functions, SAR441566 offers a promising alternative to established biologic drugs targeting TNF.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Suzanne van der Gaag, Imke H. Bartelink, Andre N. Vis, George L. Burchell, Daniela E. Oprea-Lager, Harry Hendrikse
Summary: Prostate cancer is a common malignancy in middle-aged and older men. The use of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has been approved for metastatic castration-resistant prostate cancer. Understanding the pharmacokinetics and pharmacodynamics of the ligand and the target protein is crucial for the effectiveness of RLT.
Article
Multidisciplinary Sciences
Seong Beom An, Bo-Gie Yang, Gyeonghui Jang, Do-Yeon Kim, Jiyoung Kim, Sung-Man Oh, Nahyun Oh, Sanghee Lee, Ji-Yeong Moon, Jeong-Ah Kim, Ji-Hyun Kim, Yoo-Jeong Song, Hye-Won Hyun, Jisoo Kim, Kyungwha Lee, Dajeong Lee, Min-Jung Kwak, Byung Kwon Kim, Young-Kyu Park, Chun-Pyo Hong, Jung Hwan Kim, Hye Seong Lim, Min Sook Ryu, Hyun-Tak Jin, Seung-Woo Lee, Yoon-Seok Chang, Hae-Sim Park, Young Chul Sung, Myoung Ho Jang
Summary: IgE is critical in the development of allergic diseases and its neutralization can alleviate symptoms. This study proposes the combined use of Bifidobacterium longum and a fusion protein called IgE(TRAP) to target IgE-mediated allergic reactions. The results show a reduction in mast cell and IgE levels in food allergy models, indicating a potentially potent treatment for patients with high IgE levels.
NATURE COMMUNICATIONS
(2022)
Article
Hematology
Byungdoo A. Yi, Debra Freedholm, Nancy Widener, Xiaohui Wang, Emilie Simard, Constance Cullen, Naab M. Al-Saady, Norman E. Lepor, Sara Coulter, Mark Lovern, Dan Bloomfield
Summary: Abelacimab, a novel fully human monoclonal antibody targeting Factor XI, demonstrates dual activity against the inactive and activated FXI. Studies show that abelacimab effectively reduces free FXI levels after intravenous and subcutaneous administration, with a favorable safety profile, supporting its clinical development.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Pharmacology & Pharmacy
Mark Stroh, Michelle Green, Bjorn L. Millard, Joshua F. Apgar, John M. Burke, Will Garner, Hong Lu, Susan K. Lyman, Luc R. Desnoyers, Jennifer Richardson, Alison Hannah, W. Michael Kavanaugh
Summary: CX-072 is an anti-PD-L1 Probody therapeutic designed to be preferentially activated by proteases in the tumor microenvironment. Model-guided drug development showed that the in vivo activity of CX-072 is consistent with theoretical predictions.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Infectious Diseases
Yutong Jin, David Benkeser, Maia Kipiani, Nicole F. Maranchick, Lali Mikiashvili, Ketevan Barbakadze, Zaza Avaliani, Wael A. Alghamdi, Mohammad H. Alshaer, Charles A. Peloquin, Henry M. Blumberg, Russell R. Kempker
Summary: This study investigated the potential prolongation of the QT interval caused by newer anti-tuberculosis drugs. The findings suggest that while these drugs may cause a modest increase in QTc interval, the impact on clinical outcomes is minimal.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Gastroenterology & Hepatology
Marcin Wawrzyniak, Yasser Morsy, Radoslav Mladenov, Giulia Tontodonati, Yagmur Turgay, Stefan Herwig, Jonathan Back, Manuela Mally, Amirreza Faridmoayer, Michael Scharl
Summary: The specific modification in the Fc-glycosylation pattern of anti-TNF-alpha antibodies does not affect their immunogenicity in monocyte-derived dendritic cells. Further research is needed to determine if this modification may impact the immunological profile of T- and B-cells, potentially reducing the formation of anti-drug antibodies and improving patient care.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Microbiology
Joshua A. Reeder, Cormac T. O'Sullivan, Min Xu, Nan Wu, Dilek Ince, William K. Rogers, Guohua An
Summary: The study aimed to investigate the population pharmacokinetics of ampicillin-sulbactam in surgical patients undergoing prolonged surgery with antibiotic redosing. A population pharmacokinetic model was developed, revealing that creatinine clearance and heart failure affected clearance, while body surface area influenced the central volume of distribution. Monte Carlo simulations showed that the recommended 2-hour redosing scheme was overly conservative, and a 4-hour redosing interval with a 3-g dose could achieve the desired target in all populations. The study suggests revising the current redosing guidelines and customizing prophylaxis recommendations based on local susceptibility patterns.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Review
Immunology
Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu
Summary: Immunotherapy may lead to pseudoprogression, where tumors initially grow but shrink with continued treatment. This article reports a case of pseudoprogression in a lung cancer patient receiving immunotherapy, and reviews the mechanisms, clinical manifestations, and prognostic indicators of pseudoprogression.
Article
Immunology
Ling-zhijie Kong, Ying Zheng, Kaichun Li
Summary: Treatment options for metastatic colorectal cancer are limited after second-line chemotherapy failure. In this case report, a 59-year-old male patient achieved remarkable response to fruquintinib and toripalimab combination therapy after multiple lines of chemotherapy failed. The patient had partial response within 3 months and complete response of pulmonary masses within 12 months. The combination of fruquintinib and PD-1 inhibitors improves the prognosis of metastatic colorectal cancer, with a progression-free survival of over 17 months.
